Galena Biopharma (GALE) Reports Q3 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update
November 9, 2016 4:10 PM ESTGALE-401 expected to initiate a Phase 3 clinical trial in Q2, 2017Top-Line results from NeuVax (nelipepimut-S) PRESENT Clinical TrialWebcast and conference call today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
SAN RAMON, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today reported its financial results and provided a corporate update for the quarter ended September 30, 2016.
... More